Treatment | Dose and schedule for adult patients* | Administration |
Vancomycin¶ | High flux: 20 mg/kg IV loading dose, then 1 g IV in last hour of each HD session Low flux: 500 mg in last hour of each HD session | - Use actual (ie, estimated dry) body weight to determine loading dose
|
Ceftazidime | 1 g IV post-HD | - Some centers administer a 2 g dose when the next HD session is 72 hours later
|
Cefepime | 1.5 to 2 g IV post-HD | - Alternative if ceftazidime is unavailable
- Risk of neurotoxicity in drug accumulation
- 2 g dose for pathogen MIC ≥4 mcg/mL or when next HD session is 72 hours later[1,2]
|
Cefazolin | 2 g IV post-HD | - For pathogen-directed therapy of MSSA
- Some centers administer a 3 g dose when the next HD session is 72 hours later
|
Gentamicin or tobramycin | 1 to 2 mg/kg IV in last hour of each HD session (not to exceed 100 mg per dose)Δ | - Alternative in settings with elevated rates of resistance to ceftazidime or severe hypersensitivity to third generation cephalosporins◊
- Ototoxicity in up to 20% when used >48 to 72 hours, particularly in combination with vancomycin
- Weight scalar to determine dose:
- Underweight: Use actual (dry) body weight
- Normal weight or overweight: Use IBW
- Obese (ie, >1.25 IBW): Use ABW
- A calculator for estimating IBW and ABW is available separately in UpToDate
|
Daptomycin | High flux: 9 mg/kg IV in last hour of each HD session Low flux: 7 mg/kg in last hour of each HD session | - For pathogen-directed therapy or history of vancomycin-resistant Enterococcus and an alternative in patients with documented vancomycin hypersensitivity (excluding vancomycin flushing syndrome)
|